{"id":"bimatoprost-0-01","safety":{"commonSideEffects":[{"rate":"25-45","effect":"Conjunctival hyperemia (eye redness)"},{"rate":"10-25","effect":"Iris hyperpigmentation (darkening)"},{"rate":"5-15","effect":"Eyelid skin hyperpigmentation"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Foreign body sensation"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.","oneSentence":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:59.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"},{"name":"Hypotrichosis of the eyelashes (eyelash growth)"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT06267274","phase":"PHASE1","title":"A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2024-04-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":240},{"nctId":"NCT05397600","phase":"PHASE3","title":"Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2022-06-22","conditions":"Glaucoma, Ocular Hypertension","enrollment":684},{"nctId":"NCT05729594","phase":"PHASE1","title":"Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2023-02-27","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT04285580","phase":"PHASE3","title":"A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-06-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":37},{"nctId":"NCT04890106","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mankind Pharma Limited","startDate":"2021-10-02","conditions":"Glaucoma, Open-Angle","enrollment":310},{"nctId":"NCT05401357","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2022-06-29","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":168},{"nctId":"NCT03927443","phase":"PHASE3","title":"A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-06-10","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT02448043","phase":"NA","title":"Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-06-04","conditions":"Nail Growth Cessation, Intraocular Pressure","enrollment":45},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01298700","phase":"PHASE4","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":806},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02471105","phase":"PHASE4","title":"Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":67},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT01814761","phase":"","title":"A Study of Bimatoprost 0.01% in the Clinical Setting","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-05","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":312},{"nctId":"NCT01664039","phase":"PHASE4","title":"An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Glaucoma, Ocular Hypertension","enrollment":104},{"nctId":"NCT01830140","phase":"PHASE3","title":"A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":466},{"nctId":"NCT01863953","phase":"PHASE2","title":"A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT02138461","phase":"","title":"Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops","status":"COMPLETED","sponsor":"MDbackline, LLC","startDate":"2013-10","conditions":"Glaucoma","enrollment":211},{"nctId":"NCT01547598","phase":"PHASE4","title":"Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":135},{"nctId":"NCT01271686","phase":"PHASE4","title":"24-hour IOP-lowering Effect of 0.01% Bimatoprost","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-01","conditions":"Intraocular Pressure, Glaucoma, Ocular Hypertension","enrollment":16},{"nctId":"NCT01589510","phase":"","title":"A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":419},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01489670","phase":"","title":"Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-09","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":387},{"nctId":"NCT01594970","phase":"PHASE4","title":"A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":800},{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT01833741","phase":"PHASE4","title":"A Study of LUMIGAN® RC in the Clinical Setting","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":1137},{"nctId":"NCT01568008","phase":"","title":"Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":933},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01464424","phase":"PHASE4","title":"Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-10","conditions":"Glaucoma, Ocular Hypertension, Open-Angle Glaucoma","enrollment":84},{"nctId":"NCT01253902","phase":"PHASE4","title":"Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":164},{"nctId":"NCT01628588","phase":"","title":"Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":854},{"nctId":"NCT01632423","phase":"","title":"A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":10337},{"nctId":"NCT00651859","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2002-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":111},{"nctId":"NCT00652496","phase":"PHASE2","title":"Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LUMIGAN® RC","LUMIGAN® 0.01%","Lumigan 0.01%","Lumigan® RC","Lumigan®"],"phase":"marketed","status":"active","brandName":"Bimatoprost 0.01%","genericName":"Bimatoprost 0.01%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension, Hypotrichosis of the eyelashes (eyelash growth).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}